Gene editing companies say human germline editing ‘currently inappropriate’

Thirteen gene editing companies asserted that human germline gene editing is “currently inappropriate” in a statement released by the Alliance for Regenerative Medicine on Tuesday. The companies cite unresolved “important safety, ethical, legal, and societal issues,” and say that they are “solely focused on somatic cell approaches to therapeutic treatments and cures for disease.”

The

Read the full 544 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE